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Abstract
One limitation of current biochemical or histologic analysis of advanced prostate cancer (PC; T3/T4 ± Nx Mx) is the
ability to identify on first diagnostic biopsy patients who will make a durable response to hormone ablation therapy.
The aim of this study was to assess the predictive value (sustained response to hormonal therapy and clinical
outcome (relapse-free and overall survival)) of phosphatase and tensin homolog (PTEN) and the androgen receptor
(AR) immunoexpression in the presenting biopsy. Analysis was performed on 47 samples (10 cases of benign
prostatic hyperplasia and 37 hormone-naive PCs). Patients selected represented two stages in the natural history
of PC: The “clinical metastatic androgen–responsive” (androgen-dependent PC, ADPC) and the “clinical metastatic
androgen–resistant” (androgen-independent PC, AIPC). Reduced immunoreactivity (IR) of either or both PTEN/AR
in the initial hormone-naive PC samples was observed with increased frequency in AIPCs. In the ADPC group, low
PTEN and/or AR-IR was associated with a shorter median relapse-free survival, i.e., at 30 months after surgery, the
probability of relapse-free survival for high expressors of PTEN and AR was 85.7% (SEM= 9.3) compared with only
16.6% (SEM = 15.2) in low expressors. At 36 months, only 28.5% (SEM = 9.3) of ADPC high expressors had ex-
perienced a biochemical relapse compared with 100% of low expressors (hazard ratio, 4.6; 95% confidence inter-
val, 4.7-146.8). Further studies analyzing the coexpression of PTEN and AR should be undertaken to validate this
pilot study and the utility of these biomarkers in routine histopathologic workup of patients with PC.
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Introduction
Prostate cancer (PC) is the most common non dermatological epi-
thelial cancer in men in developed countries accounting for approxi-
mately 15.3% of all male malignancies [1]. In up to 80% of patients
with locally advanced (T3/T4 N0 M0) or metastatic (T3/T4 Nx M1),
the disease responds to primary androgen ablation therapy [AAT;
orchidectomy or administration of luteinizing hormone–releasing
hormone (LHRH) agonists with or without antiandrogens]. A re-
sponse to AAT averaging approximately 18 months is seen in most
patients with androgen-dependent metastatic PC (ADPC) [2]. Dis-
ease relapse then ensues possibly because aberrant androgen receptor
(AR) signaling and/or the activation of alternative signaling path-
ways and continues to progress as hormone refractory or androgen-
independent PC (AIPC) [3,4].
Routine screening tests, in particular, measurement of the serum
level of prostate-specific antigen (PSA), have significantly increased
the rate of early detection of PC. Together with pathologic stag-
ing and Gleason grade, PSA level also governs decision making and
Abbreviations: AAT, androgen ablation therapy; AD, androgen dependence/dependent;
AI, androgen independence/independent; AR, androgen receptor; BPH, benign prostatic
hyperplasia; IHC, immunohistochemistry; LI, labeling index; PC, prostate cancer
Address all correspondence to: Professor El-Nasir Lalani, Department of Histopathology
andMicrobiology, Aga KhanUniversity, POBox 3500, StadiumRoad, Karachi, Pakistan,
74800. E-mail: elnasir.lalani@aku.edu
Received 14 May 2008; Revised 6 June 2008; Accepted 8 June 2008
Copyright © 2008 Neoplasia Press, Inc. All rights reserved 1522-8002/08/$25.00
DOI 10.1593/neo.08582
www.neoplasia.com
Volume 10 Number 9 September 2008 pp. 949–953 949
prognosis in PC. However, due to the heterogeneity of tumors and
variability in progression of PCs of different grades, commonly used
diagnostic methods fail to discriminate between indolent tumors that
do not require aggressive treatment from those that will progress
after conventional treatments. There is, therefore, a need to identify
markers that could aid in early differentiation between these two dis-
tinct clinical phenotypes, thus enabling better prognostication.
PTEN (phosphatase and tensin homolog deleted on chromosome
10), a negative regulator of phosphatidylinositol 3-kinase/Akt signal-
ing, thus far, is the most frequently mutated tumor-suppressor gene
in PC [5], where deletions, point mutations, and DNA methylation
are reported to occur. However, because alterations of the PTEN gene
are late events in PC progression, loss of protein expression correlates
well with a high (>7) Gleason grade [5] but assessment of PTEN ex-
pression is of little value as a sole prognostic marker.
Increasing evidence points to a strong correlation between per-
turbations in the AR and PTEN/Akt signaling axis and PC progres-
sion [6–8]. Results from several in vitro studies using established
PC cell lines have demonstrated that PTEN and Akt are, respec-
tively, negative and positive modulators of AR transcriptional activity
[7,9]. Under experimental conditions, PTEN and AR exert opposite
effects on cell growth and apoptosis. Moreover, Wu et al. [10] in
a recent study demonstrated that conditional expression of PTEN
alters responsiveness of LNCaP, an androgen-responsive PC cell line,
to antiandrogens.
The aim of this pilot study was to assess the potential benefit of
analyzing immunohistochemical coexpression of PTEN and AR in
the initial hormone-naive (not subjected to AAT) biopsies from pa-
tients with PC, as a possible predictor of sustained responsiveness to
hormone therapy.
Materials and Methods
This is a retrospective pilot study of two distinct cohort groups,
representing two clinical tumor phenotypes (ADPC and AIPC), as
determined in a 2-year follow-up. To satisfy the criteria set up for
the study, a relatively small number of cases could be selected from
the hospital database and included in the analysis.
Samples and Patient Selection
The study included 47 transurethral prostatic resections samples
[10 benign prostatic hyperplasia (BPH) and 37 advanced PCs] se-
lected from the archives of the Hammersmith Hospital, London,
from patients treated during the period from 1990 to 2001 (Local
Research Ethics Committee approval no. 2001/6023). Age range
was 52 to 65 years (median, 55.8 years) for patients with BPH
and 55 to 90 years (median, 70.9 years) for patients with PC. All
PC patients had stage III/IV disease (T3/T4 Nx M0 or Tx Nx M1)
and the majority were of high Gleason grade (≥7). Prostate-specific
antigen level at the time of surgery was ≤10 ng/ml in only 10 of
37 patients.
Groups. Prostate cancer patients were categorized by androgen
sensitivity at the time of biopsy and ascribed to two groups:
Group 1: ADPC (20 patients)— patients who, after surgery, re-
ceived and responded to AAT and, for at least 18 months, dem-
onstrated no evidence of clinical or biochemical progression;
Group 2: AIPC (17 patients)— patients with documented clin-
ical and biochemical progression while receiving AAT for at
least 2 years after surgery.
Treatment
Treatment regimen included either a combination of an anti-
androgen and LHRH analogues (18 patients), antiandrogens and
orchidectomy (8 patients), LHRH analogues only (3 patients), and
antiandrogen therapy (2 patients). Four patients underwent orchid-
ectomy but did not receive any systemic hormone therapy, whereas
two patients were treated by LHRH analogues, antiandrogens, orchid-
ectomy, and diethylstilbestrol in the AIPC group. None of the
patients received neoadjuvant hormonal therapy, radiotherapy, or cyto-
toxic chemotherapy.
Measurements
Evidence of clinical progression was defined as development of
metastases and/or clinically assessed size increase of the prostate gland
irrespective of PSA values. Follow-ups were available in all cases, and
PC was defined as cause of death in patients dying after documenta-
tion of clinical progression. The main end point was survival dura-
tion, that is, the time between obtaining the specimen and death and
median observation time was 36 months [95% confidence interval
(CI), 33.65-55.05].
Clinicopathologic characteristics of AD and AI PC patients are
summarized in Table 1.
Immunohistochemistry
Paraffin sections (5 μm) cut from formalin-fixed tissue blocks were
mounted on positively charged glass slides (VWR International, UK)
and processed for conventional histologic diagnosis and immuno-
histochemistry (IHC) using the avidin-biotin-peroxidase complex
(ABC) method [11]. Immunostaining for AR (mouse antihuman
Table 1. Clinicopathologic Characteristics and Immunohistochemical LI of BPH and PC Cases.
BPH AD AI
No. of patients (% of total) 10 (21%) 20 (43%) 17 (36%)
Age (years)
Median 55.8 69.8 72
Range 52-65 55-90 60-85
Gleason score
<7 NR 6 (30%) 3 (18%)
7 6 (30%) 4 (24%)
≥7 8 (40%) 10 (58%)
TNM stage
T3/4 Nx M0 NR 16 (80%) 7 (41%)
Tx Nx M1 4 (20%) 10 (59%)
Preoperative PSA (ng/ml)
<10 10 4 4
≥10 0 16 13
Treatment
Monotherapy NR 4 5
MAB 16 12
Survival (months)
Median NR* 66 12
95% CI 51.5-78.7 11.8-29.7
IHC LI (mean ± SEM)
AR 220 ± 30.12 180.4 ± 15.78 130.6 ± 19.09
PTEN 284 ± 10.85 169.7 ± 21.88 110.6 ± 20.18
MAB indicates monoclonal antibody; NR, not relevant.
*Only survival differed significantly between AD and AIPC patients (P < .001).
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AR; BioGenex Laboratories, San Ramon, CA) and PTEN (mouse
antihuman PTEN; Neomarkers, Fremont, CA) was carried out after
antigen retrieval by boiling the sections in 10 mM citrate buffer
(pH 6.0) in a conventional microwave oven for 15 minutes. The
anti-PTEN monoclonal antibody recognizes an epitope at the C-
terminus of PTEN, which has been shown to be lost in a range of
human tumors [12].
To validate specificity of immunostaining, negative and positive PC
cell line controls were included in the analysis: 1) LNCaP (AR+/
PTEN−; PTEN deletion of one allele and a mutation of the other
PTEN allele) and 2) DU145 (AR−/PTEN+; a heterozygous point mu-
tation in exon 5 that does not affect PTEN protein expression) [13].
Before fixation of the pellets in formalin and processing for immuno-
cytochemistry, cells were routinely grown in DMEM (Invitrogen, UK)
medium supplemented with 10% fetal bovine serum (FBS; Invitrogen).
For each tissue sample, immunostaining was assessed by two in-
dependent observers. The entire section was assessed at low (100×)
and high (400×) power, and 10 high-power fields (at least 1000 cells
per patient) were analyzed. Selection of the most positive areas was
avoided to prevent overestimation of reactivity. The fraction of im-
munoreactive cells was calculated as a percentage, and immuno-
reactivity in <10% of cells was considered as negative. Intensity of
expression was evaluated and a score of 1, 2 or 3 was assigned to
reflect focal/weak, moderate or high reactivity, respectively. An over-
all labeling index (LI) that ranged between 0 and 300 was calculated
by multiplying the percentage (0-100%) of immunoreactive cells by
the IHC intensity of expression (score range, 1-3).
Statistical Analysis
Scores were clustered into two groups using the median value as
a cutoff point: high or low expressors. Fisher’s exact test was used
to compare clinicopathologic features of the two groups and to inves-
tigate whether combined expression of more than one variable was
associated with development of AI state. Survival proportions in
the groups were estimated by the Kaplan-Meier method and com-
pared by log rank test. Statistical analyses were performed in either
the Statistical Packaged for Social Science (SPSS v 9.0; SPSS, Inc.,
Chicago, IL) or in GraphPad Prism 3.2 (GraphPad Software, San
Diego, CA).
Results
Androgen-Dependent PC and Androgen-Independent
PC Groups
Androgen-dependent PC specimens were derived from hormone-
naive tumors that were treated either immediately after biopsy (12/
20 cases) or within 1 or 2 years (8 patients). These patients did not
progress biochemically or clinically in the absence of androgen for
18 months or longer.
Androgen-Independent PC samples were derived from tumors,
which, after an initial response to AAT, relapsed and continued
to progress.
Fisher’s exact test confirmed that clinicopathologic characteristics,
including Gleason grade and stage, did not differ significantly be-
tween ADPC and AIPC groups, except for survival. This secured
the elimination of the potential impact of these factors on the expres-
sion of the evaluated markers, thus, ascribing any differences detected
to hormonal responsiveness rather than to disease progression.
Immunohistochemistry—Cellular Localization of AR
and PTEN
Controls.
A. Cell lines
LNCaP: there was no detectable immunoreactivity for PTEN
(Figure 1F ), and AR was expressed in the nuclei of the cells
(Figure 1G ).
DU145: PTEN expression was strong and restricted to the
cytoplasm (Figure 1D), and cells were found not to express
the AR (Figure 1E ).
B. Benign prostatic hyperplasia cases
Immunoreactivity for 1) AR was observed in the nuclei and
2) PTEN in the cytoplasm of luminal cells. Some reactivity of
the latter was also found in stromal cells. Immunohistochemical
labeling indices (LIs) were 220 ± 30.12 for AR and 284 ± 10.85
for PTEN.
C. Prostate cancer cases
Androgen receptor was expressed in the nuclei of all except
for two AIPC cases (cytoplasmic expression), whereas in all
cases, PTEN expression was localized to the cytoplasm. Andro-
gen receptor and PTEN expressions were higher in ADPC com-
pared to AIPC, but these were not significant (P = .0503 and
P = .0583, respectively). When stratified according to the me-
dian and analyzed together, 14 (70%) of 20 ADPC samples
were found to be high expressors of both PTEN and AR com-
pared to only 4 (24%) of 17 AIPC (Figure 1A). This difference
was statistically significant (P = .0081; odds ratio, 7.583; 95%
CI, 1.737-33.101).
In addition, a positive linear association was identified between
PTEN and AR in both ADPC and AIPC cases (rs = 0.6604, P =
.0015 and rs = 0.6320, P = .0065). Immunostaining of serial sections
showed that strong AR expression was observed in areas where
PTEN was strongly positive and vice versa (Figure 1, B and C ).
Relationship between AR/PTEN and Survival
The median survival time was 66 months (95% CI, 51.5-78.7) for
the ADPC patients and 12 months (95% CI, 11.86-29.3) for the
AIPC patients (Table 1). In the ADPC group, two groups of patients
with different prognosis could be identified according to the co-
expression of AR and PTEN. To compare the prognostic impact
of AR and PTEN on survival, high and low expressors were catego-
rized according to the median of each group and a Kaplan-Meier
survival curve was plotted for each of these variables. The median
relapse-free survival for low and high expressors (of both AR and
PTEN) was 27 and 60 months, respectively (ratio, 0.45; P = .0002;
95% CI, 0.07469-0.8253; Figure 1H). In the group with reduced ex-
pression of either AR and/or PTEN, only 49% (95% CI, 33-66%)
were alive at 6 years (P = .008). There was a trend to reduced survival
in AI patients with reduced expression of AR and/or PTEN but it was
not statistically significant.
Discussion
The complementary role of PTEN and AR in prostatic epithelium
is corroborated by evidence derived from in vivo and in vitro studies.
Benign columnar prostatic epithelium, which requires androgen for
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Figure 1. (A) Correlation between PTEN and AR expression in PC and increased frequency of high expressors of PTEN and AR in AD PC.
Immunohistochemistry LI of PTEN and AR were directly (continuous line) correlated in ADPC (closed circle) and AIPC (open circle; rs =
0.6604, P = .0015 and rs = 0.6320, P = .0065). Dotted lines passing through the median value of each IHC LI identify the region where
most ADPC and only a few of AIPC cases are observed (high expressors). Most of AIPC cases are scattered outside this area. (B and C)
Expression of AR (right) and PTEN (left) in serial sections of PC. Photomicrographs show adjacent PC areas where AR and PTEN are
differentially expressed. Cytoplasmic expression of PTEN is associated with strong AR nuclear reactivity. In areas where PTEN is nega-
tive, AR is confined to the cytoplasm (original magnification, ×200). (D–G) DU145 and LNCaP as controls for PTEN and AR antibodies.
DU145 cells expressed cytoplasmic PTEN (D) but were AR-negative (E). Conversely, nuclear expression of AR was observed in LNCaP
cells (G), whereas PTEN was absent (F). (H) Kaplan-Meier curve showing relapse-free survival in ADPC patients stratified by PTEN and
AR coexpression levels. High expressors and low expressors are represented by a continuous and an interrupted line, respectively. Log
rank test was used to compare curves. P < .05 was considered significant. Time until disease recurrence (relapse-free survival) was
measured from the date of surgery until the development of metastases and/or bladder outlet obstruction (clinical relapse) or three
consecutive increases in the PSA level greater than the nadir (biochemical relapse). At 30 months after surgery, the probability of
relapse-free survival for high expressors of PTEN and AR among AD patients was 85.71% (SEM = 9.35) compared to only 16.67%
(SEM = 15.21) in low expressors. At 36 months, only 28.57% (SEM = 9.35) of high expressors had experienced a biochemical relapse
compared to 100% of low expressors (hazard ratio, 4.65; 95% CI, 4.719-146.8).
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its continuous maintenance, expressed both PTEN and AR; however,
basal cells, which are considered to be AI [14], lacked both markers.
Molecular studies have suggested an antagonistic interaction between
PTEN and AR in controlling proliferation and apoptosis of prostatic
cells, maintaining homeostasis of prostatic epithelium in adult males
[7,15,16]. In PC, the transcriptional activity of the AR is inhibited
by PTEN in ADPC, but the role of PTEN in AIPC is still unclear.
In a recent study, Wu et al. [10] showed that PTEN induction may
confer enhanced responsiveness to the antiproliferative effects of anti-
androgens in the LNCaP PC cell line. These data together with our
initial observations suggest a functional relationship between PTEN
and AR and responsiveness to AAT.
We observed heterogeneous PTEN/AR immunoexpression within
the same tumor; areas of cells strongly immunoreactive for both
PTEN and nuclear AR were often juxtaposed to foci of PTEN-
negative cells with AR expression restricted to the cytoplasm. The
AR has been implicated in nontranscriptional activity outside the
nucleus [17] such as direct protein-protein interactions with fork-
head [18]. It is conceivable that in PTEN deficient cells, AR/FKHR
complex is sequestered in the cytoplasm [19]. Although our study
implies an association between PTEN/AR coexpression and respon-
siveness to AAT, our data are observational and do not allow any
mechanistic interpretation of the PTEN and AR protein distribution.
Despite a considerable number of publications assessing the ability
of biomarkers to predict PC relapse, clinicians still rely on conven-
tional prognostic indicators in routine decision making. In breast
cancer, immunohistochemical assessment of estrogen, progesterone
and HER2 receptors is part of the routine histopathologic workup.
In this pilot report, we have demonstrated a correlation between
coexpression of PTEN and AR and the response to hormonal treat-
ment and survival in ADPC. Reduced expression of either marker
was associated with the development AI and reduced survival in pa-
tients whose tumors remained AD. Our data suggest that assessment
of PTEN/AR coexpression might prove useful in distinguishing PCs
with a more favorable prognosis from those with a high likelihood
of developing recurrence and AI disease. Our data also suggest that
restoration of PTEN activity or function could be used jointly with
AAT to maintain androgen responsiveness and possibly delay the
emergence of AIPC.
Further investigation on a larger patient cohort should be under-
taken to validate our initial results to assess reproducibility and use-
fulness of this potential new predictive indicator.
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